DEF 14A: IQVIA Reports Strong 2025 Results Amid Industry Headwinds

IQVIA Holdings Inc. delivered robust financial performance in 2025, with significant revenue and EPS growth, driven by strategic investments in AI and R&D, despite challenging macroeconomic and industry conditions.

Summary

• IQVIA achieved $16.3 billion in revenue in 2025, representing a 5.9% growth compared to 2024.
• Adjusted EBITDA increased by 2.8% to $3.8 billion, and Adjusted Diluted Earnings per Share grew by 7.1% to $11.92.
• Free Cash Flow was strong at $2.1 billion, achieving 99% of Adjusted Net Income, exceeding the target range of 80% to 90%.
• The company invested $1.8 billion in strategic acquisitions and other investments and returned $1.2 billion to stockholders through share repurchases of approximately 7.4 million shares.
• Research & Development Solutions (R&DS) delivered a record contracted backlog of $32.7 billion, a 5.3% increase from 2024, and added over 400 net new R&DS clients.
• Technology & Analytics Solutions (TAS) and Contract Sales & Medical Solutions (CSMS) reported full-year revenue growth of 7.6% and 9.7% respectively.
• IQVIA advanced its AI strategy by expanding partnerships, launching new AI-enabled solutions, and filing over 90 AI-related patent applications in 2025.
• The Board appointed Dr. William G. Kaelin, Jr., a Nobel Laureate, to the Board in 2025, enhancing scientific expertise.
• Michael J. Fedock was selected to succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer, effective February 28, 2026.
• A stockholder proposal for an independent Board Chairman was presented, which the Board unanimously recommends voting AGAINST, citing the need for flexibility in leadership structure and existing strong governance.
• The company maintained a multi-year favorable attrition trend at 10.5% in 2025 and exceeded Fortune 500 benchmarks for key employee engagement metrics.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to strong financial performance and strategic advancements in AI and R&D, achieved despite significant industry headwinds. The proactive management of challenges and commitment to innovation are key strengths, though below-target performance share payouts for two consecutive years warrant attention.

Positives

• Revenue grew by 5.9% to $16.3 billion in 2025, demonstrating strong top-line performance.
• Adjusted Diluted EPS increased by 7.1% to $11.92, indicating improved profitability on a per-share basis.
• Free Cash Flow reached $2.1 billion, representing 99% of Adjusted Net Income, significantly exceeding the 80-90% target.
• R&DS achieved a record contracted backlog of $32.7 billion, up 5.3% from 2024, signaling future revenue potential.
• Over 400 net new R&DS clients were added, with strong momentum among emerging biopharmaceutical companies.
• TAS and CSMS segments exceeded expectations with 7.6% and 9.7% revenue growth, respectively.
• Significant investment in innovation, including $1.8 billion in strategic acquisitions and other investments.
• Repurchased approximately 7.4 million shares, returning $1.2 billion to stockholders.
• Refinanced over $6 billion of debt, strengthening the capital structure and enhancing operational efficiencies.
• Advanced AI strategy with new AI-enabled solutions, expanded partnerships, and over 90 AI-related patent applications filed.
• IQVIA was recognized as the No. 1 most admired company in its category on the Fortune World's Most Admired Companies list for the fifth consecutive year.
• Employee engagement metrics exceeded Fortune 500 benchmarks, with 91% of employees acquiring necessary skills and 95% understanding how to raise ethical concerns.
• Continued achievement of 100% My Green Lab certification across all laboratories, with energy-saving initiatives avoiding over 765 metric tons of CO2 emissions.

Negatives

• Adjusted EBITDA growth of 2.8% was lower than revenue growth, suggesting some margin pressure.
• The company faced industry challenges including heightened geopolitical tensions, U.S. healthcare policy shifts, persistent macroeconomic pressures (high interest rates), constrained biopharmaceutical funding, and delayed customer decision-making.
• IQVIA's stock price was adversely impacted in the first half of 2025, falling from $209.96 to $137.00 at mid-year, before recovering.
• The 2023-2025 performance share awards paid out at 80.9% of target, below the 100% target, due to below-target Adjusted Diluted EPS growth and relatively poor stock price performance during the period.
• The 2022-2024 performance shares also paid out below target at 53.5%, marking two consecutive years of below-target performance share payouts.

Risks

• Business disruptions caused by natural disasters, pandemics, international conflicts, or other disruptions outside of company control.
• Most contracts may be terminated on short notice, leading to potential loss or delays with large client contracts.
• The market for services may not grow as expected.
• Inability to successfully develop and market new services or enter new markets.
• Imposition of restrictions on data use by suppliers or refusal to license data.
• Failure to comply with contractual, regulatory, or ethical requirements, including changes to data protection and privacy laws.
• Breaches or misuse of security or communications systems.
• Failure to meet productivity or business transformation objectives.
• Failure to successfully invest in growth opportunities.
• Ability to protect intellectual property rights and susceptibility to infringement claims.
• Expiration or inability to acquire third-party licenses for technology or intellectual property.
• Failure to accurately and timely price and formulate cost estimates for contracts, or to document change orders.
• Hardware and software failures, delays in computer and communications systems, or failure to implement system enhancements.
• The rate at which backlog converts to revenue.
• Ability to acquire, develop, and implement technology necessary for the business.
• Consolidation in the industries in which clients operate.
• Risks related to client or therapeutic concentration.
• Government regulators or customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market.
• Government regulators may impose new regulatory requirements or adopt new regulations affecting the biopharmaceutical industry.
• Risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance (e.g., anti-corruption laws).
• Risks related to the enactment of legislation or the imposition of regulations or other restrictions or actions by governments that create business uncertainty and limit trade.
• Changes in accounting standards.
• General economic conditions, including financial market conditions, inflation, and risks related to sales to government entities.
• Impact of changes in tax laws and regulations.
• Ability to successfully integrate and achieve expected benefits from acquired businesses.
• Potential for the reorganized business segment structure to not achieve expected benefits.

Future Outlook

IQVIA anticipates continued growth driven by its long-term growth algorithm, which includes customer R&D and SG&A spending growth (3-5%), additional outsourcing to IQVIA (1%), go-to-market and innovation strategies (1%), and strategic acquisitions (1-2%). The company is confident in its ability to create meaningful impact and advance its mission in an evolving healthcare landscape, particularly through continued leadership in AI, data science, and medical innovation.

Management Comments

• John M. Leonard, M.D., Lead Independent Director: "The Board works closely with our Chief Executive Officer and senior management to formulate and oversee the Company's long-term strategy to ensure that we are well positioned to succeed in a complex and rapidly changing healthcare and macroeconomic environment."
• John M. Leonard, M.D., Lead Independent Director: "We welcomed Dr. William G. Kaelin, Jr. to the Board in 2025. Bill is a Nobel Laureate, scientist, academic, and physician who provides valuable leadership and decades of experience in medical research and discovery, particularly in oncology."
• John M. Leonard, M.D., Lead Independent Director: "In 2025, following a thoughtful and deliberate Chief Financial Officer succession process, Michael J. Fedock was selected to succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer of IQVIA, effective February 28, 2026."
• Ari Bousbib, Chairman and Chief Executive Officer: "2025 was a year defined by industry challenges, including heightened geopolitical tensions; U.S. healthcare policy shifts; persistent macroeconomic pressures, including high interest rates; constrained biopharmaceutical funding and capital availability; and uncertainty across the industry and global markets, resulting in delayed customer decision-making."
• Ari Bousbib, Chairman and Chief Executive Officer: "Through these efforts, IQVIA delivered strong financial and operational performance, and advanced our strategic priorities in our mission to improve patient outcomes."
• Ari Bousbib, Chairman and Chief Executive Officer: "AI continues to redefine the life sciences landscape. We advanced our AI strategy by expanding key partnerships to strengthen ecosystem interoperability, launching new AI-enabled solutions across multiple business units and positioning IQVIA for sustained growth through the development of AI agents for both internal use and external offerings."
• Ari Bousbib, Chairman and Chief Executive Officer: "I am pleased with the successful process that led to the appointment of Michael J. Fedock as our new Executive Vice President and Chief Financial Officer, effective February 28, 2026."
• Ari Bousbib, Chairman and Chief Executive Officer: "I am proud of all we accomplished in 2025. Above all, I am deeply grateful for the resilience, ingenuity and dedication of our employees and for the trust placed in us by our stockholders, customers and partners."

Industry Context

StockSavvy.ai notes that IQVIA's 2025 performance demonstrates resilience in a challenging biopharmaceutical and macroeconomic environment. The company's strategic focus on AI, particularly its 'Healthcare-grade AI' framework and partnerships with major tech firms like NVIDIA and AWS, positions it at the forefront of digital transformation in life sciences. This proactive stance contrasts with broader industry headwinds, such as constrained biopharmaceutical funding and policy shifts, which have impacted customer decision-making and clinical trial activity. IQVIA's ability to grow its R&DS backlog and commercial solutions revenue, while competitors face challenges, suggests a strong competitive position, particularly through its integrated ecosystem approach, which directly addresses concerns raised by analysts about competition from more innovative players.

Comparison to Industry Standards

• IQVIA's R&DS segment delivered an industry-leading, record contracted backlog of $32.7 billion, indicating strong future business compared to its peers in the Contract Research Organization (CRO) sector.
• The company's 10.5% voluntary attrition rate in 2025 is described as 'favorable' and 'well below pre-pandemic levels,' suggesting better talent retention than some industry averages that may still be recovering from post-pandemic labor market shifts.
• IQVIA's recognition as the No. 1 most admired company in the 'Healthcare: Pharmacy and Other Services' category on Fortune's World's Most Admired Companies list for the fifth consecutive year, and its top ranking in Everest Group's Life Sciences AI and Analytics Services for Commercial PEAK Matrix Assessment 2025, including for generative AI leadership, positions it as a leader in innovation and service quality compared to global benchmarks.
• The company's achievement of 100% My Green Lab certification across all laboratories, with its Singapore lab attaining 'Green-Level' certification and Edinburgh winning the 'International Freezer Challenge,' demonstrates a commitment to sustainability that exceeds many industry standards for laboratory operations.

Management Changes

Corporate Governance

Related Party Transactions

• BlackRock, Inc., a beneficial owner of approximately 8.9% of IQVIA's common stock, entered into an agreement with an IQVIA subsidiary to license certain IQVIA information assets with a total contract value of $668,800. This transaction was approved by the Audit Committee and conducted in the ordinary course of business on an arms-length basis.

Stakeholder Impact

• Shareholders: Benefited from strong financial performance, share repurchases ($1.2 billion), and debt refinancing. The Board's recommendation against the independent chairman proposal indicates a potential point of contention for some shareholders, but overall engagement is high.
• Employees: Benefited from continued investment in learning and development, including AI and data analytics upskilling programs (230,000+ engagements). High employee engagement (85% seeing link to vision, 91% acquiring skills) and favorable attrition rates (10.5%) indicate positive impact.
• Customers: Benefited from expanded AI-enabled solutions, strategic acquisitions strengthening capabilities, and continued support for critical programs from clinical trials to commercialization. Increased customer satisfaction scores were noted in tech and analytics.
• Patients: Impacted by IQVIA's mission to accelerate innovation for a healthier world, including advancing critical trials, launching innovative treatments, expanding evidence-based patient research, and supporting public health initiatives globally (e.g., disease outbreaks in Africa).
• Suppliers/Partners: Engaged through strategic partnerships (e.g., Amazon Web Services, Databricks, Microsoft, NVIDIA) to strengthen ecosystem interoperability and deliver transformative technology.

Next Steps

• Annual election of director nominees at the 2026 Annual Meeting on April 23, 2026.
• Advisory (nonbinding) vote to approve executive compensation at the 2026 Annual Meeting.
• Ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026 at the 2026 Annual Meeting.
• Approval of IQVIA Holdings Inc. 2026 Incentive and Stock Award Plan at the 2026 Annual Meeting.
• Consideration of a stockholder proposal for an independent Board Chairman at the 2026 Annual Meeting.
• Continued engagement with stockholders throughout 2026.
• Michael J. Fedock to assume role of Executive Vice President and Chief Financial Officer effective February 28, 2026.
• Implementation of a new, simplified organizational model starting in the first quarter of 2026, consisting of Commercial Solutions and Research & Development Solutions segments.

Key Dates

Recommendation

IQVIA demonstrated strong financial performance in 2025, exceeding analyst estimates for key metrics like Adjusted EPS and Free Cash Flow, despite significant industry headwinds and macroeconomic challenges. The company's aggressive investment in AI and strategic acquisitions positions it well for future growth in the evolving healthcare landscape. However, the stock's volatility in 2025, with a significant mid-year dip, and two consecutive years of below-target performance share payouts, suggest that while the long-term outlook is positive, near-term execution risks and industry pressures remain. The Board's opposition to the independent chairman proposal, while not immediately impacting financials, could be a governance concern for some investors. Given the strong recovery in the latter half of 2025 and continued strategic investments, a 'hold' recommendation allows investors to maintain exposure to IQVIA's growth potential while acknowledging ongoing market and governance considerations.

Keywords

IQVIA, SEC Filing, DEF 14A, Proxy Statement, Financial Performance, Revenue Growth, Adjusted EBITDA, Adjusted Diluted EPS, Free Cash Flow, Clinical Research, R&D Solutions, Technology & Analytics, Contract Sales, Medical Solutions, Artificial Intelligence, AI Strategy, Healthcare Technology, Biopharmaceutical Industry, Corporate Governance, Executive Compensation, Board of Directors, Shareholder Engagement, Sustainability, Risk Management, Capital Deployment, Stock Repurchase, Debt Refinancing, Patient Research, Public Health, Talent Management